Transcat, Inc. (NASDAQ:TRNS) Receives $105.33 Consensus Price Target from Brokerages

Transcat, Inc. (NASDAQ:TRNS) has received a consensus recommendation of “Hold” from the five analysts that are currently covering the stock, Marketbeat reports. Two analysts have rated the stock with a sell recommendation, two have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year price objective among brokers that have issued a report on the stock in the last year is $105.3333.

TRNS has been the topic of several research analyst reports. Zacks Research cut Transcat from a “hold” rating to a “strong sell” rating in a report on Tuesday, February 3rd. Weiss Ratings restated a “sell (d+)” rating on shares of Transcat in a report on Monday, December 29th.

Transcat Trading Up 0.4%

Shares of NASDAQ TRNS opened at $78.30 on Friday. The stock has a market capitalization of $730.54 million, a P/E ratio of 92.12 and a beta of 0.79. Transcat has a 1-year low of $50.23 and a 1-year high of $97.08. The company has a debt-to-equity ratio of 0.34, a current ratio of 2.21 and a quick ratio of 1.85. The business has a fifty day moving average price of $64.85 and a 200 day moving average price of $68.15.

Transcat (NASDAQ:TRNS) last issued its quarterly earnings results on Tuesday, February 3rd. The scientific and technical instruments company reported $0.26 earnings per share for the quarter, missing analysts’ consensus estimates of $0.30 by ($0.04). The business had revenue of $83.86 million for the quarter, compared to analysts’ expectations of $80.99 million. Transcat had a return on equity of 6.15% and a net margin of 2.47%. Equities research analysts expect that Transcat will post 2.3 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. Vanguard Group Inc. increased its stake in Transcat by 0.4% in the 3rd quarter. Vanguard Group Inc. now owns 530,771 shares of the scientific and technical instruments company’s stock valued at $38,852,000 after buying an additional 2,041 shares during the period. Royce & Associates LP raised its stake in Transcat by 15.3% in the 4th quarter. Royce & Associates LP now owns 390,546 shares of the scientific and technical instruments company’s stock valued at $22,156,000 after purchasing an additional 51,774 shares during the last quarter. Dimensional Fund Advisors LP lifted its stake in shares of Transcat by 5.4% during the 4th quarter. Dimensional Fund Advisors LP now owns 252,767 shares of the scientific and technical instruments company’s stock worth $14,340,000 after purchasing an additional 12,935 shares during the period. Wellington Management Group LLP lifted its holdings in shares of Transcat by 677.7% during the 4th quarter. Wellington Management Group LLP now owns 248,539 shares of the scientific and technical instruments company’s stock worth $14,100,000 after acquiring an additional 216,579 shares during the period. Finally, Bessemer Group Inc. raised its position in shares of Transcat by 35.8% in the 2nd quarter. Bessemer Group Inc. now owns 244,491 shares of the scientific and technical instruments company’s stock worth $21,016,000 after buying an additional 64,422 shares during the period. 98.34% of the stock is owned by hedge funds and other institutional investors.

Transcat Company Profile

Transcat, Inc (NASDAQ: TRNS) is a leading provider of calibration, laboratory, and metrology services in North America. Founded in 1964 and headquartered in Ronkonkoma, New York, the company specializes in ensuring the accuracy and compliance of measurement instruments across a wide range of industries. Transcat operates a network of ISO/IEC 17025–accredited laboratories and offers on-site field calibration, instrument repair, and preventive maintenance services.

In addition to its calibration services, Transcat distributes precision instrumentation and related software solutions from top manufacturers.